Salvage radiotherapy for palpable, locally recurrent prostate cancer after radical prostatectomy.

PURPOSE A retrospective study to evaluate the outcome of salvage radiotherapy (RT) for clinically apparent, palpable prostate cancer recurrence after radical prostatectomy (RP). METHODS AND MATERIALS Forty-two patients underwent RT for clinically apparent recurrent prostate cancer after RP between 1993 and 1999. The end points and treatment variables of biochemical disease-free survival were evaluated statistically. RESULTS The median follow-up was 4.3 years. All 42 patients experienced resolution of clinically detectable recurrence within 1 year after RT. The 5-year biochemical disease-free survival, local control, freedom from distant metastases, and overall survival rate was 27%, 94%, 82%, and 78%, respectively. The initial pathologic stage (T3 or T4; p = 0.04) and interval (<2 years from RP to RT; p = 0.01) were independent predictors of biochemical failure, and RT simulation without contrast (p = 0.05) was nearly significant on multivariate analysis. Three patients (7%) experienced chronic Grade 3 or 4 RT-related toxicity. CONCLUSION Salvage prostate bed RT for clinically apparent locally recurrent prostate cancer after RP provides effective local tumor control with modest durable biochemical control. Patients irradiated with a better simulation technique were found to have a more favorable outcome. A consensus on a definition of biochemical disease-free survival after salvage RT is critical for meaningful comparison of the available data and to future progress in treating this disease process.

[1]  E. Venkatraman,et al.  Predictors of biochemical outcome with salvage conformal radiotherapy after radical prostatectomy for prostate cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  S. Schild,et al.  Evaluation of serum prostate-specific antigen levels after postoperative radiation therapy for pathologic stage T3, N0 prostate cancer. , 1996, Mayo Clinic proceedings.

[3]  P. Carroll,et al.  Local recurrence after radical prostatectomy: characteristics in size, location, and relationship to prostate-specific antigen and surgical margins. , 1996, Urology.

[4]  J. Stanford,et al.  Population-based prostate cancer trends in the United States: patterns of change in the era of prostate-specific antigen , 2005, World Journal of Urology.

[5]  M. Pike,et al.  Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples. , 1977, British Journal of Cancer.

[6]  T. Wiegel,et al.  Re: Postoperative radiotherapy for stage pT3 carcinoma of the prostate: improved local control. , 1997, The Journal of urology.

[7]  J. Forman,et al.  Therapeutic radiation in patients with a rising post-prostatectomy PSA level. , 1998, Oncology.

[8]  P. Carroll,et al.  Radiation therapy for the management of biopsy proved local recurrence after radical prostatectomy. , 1998, The Journal of urology.

[9]  E. B. Butler,et al.  Prediction of response to salvage radiation therapy in patients with prostate cancer recurrence after radical prostatectomy. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  S. Levitt,et al.  Delayed/salvage radiation therapy in patients with elevated prostate specific antigen levels after radical prostatectomy: A long term follow‐up , 1996 .

[11]  D. Cox Regression Models and Life-Tables , 1972 .

[12]  C. Catton,et al.  Adjuvant and salvage radiation therapy after radical prostatectomy for adenocarcinoma of the prostate. , 2001, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[13]  S. Schild,et al.  The use of radiotherapy for patients with isolated elevation of serum prostate specific antigen following radical prostatectomy. , 1996, The Journal of urology.

[14]  M S Anscher,et al.  Radiotherapy for a rising prostate-specific antigen after radical prostatectomy: the first 10 years. , 2000, International journal of radiation oncology, biology, physics.

[15]  James D. Cox,et al.  Consensus statement: Guidelines for PSA following radiation therapy , 1997 .

[16]  C. Danjoux,et al.  (IN)-efficacy of salvage radiotherapy for rising PSA or clinically isolated local recurrence after radical prostatectomy. , 2002, International journal of radiation oncology, biology, physics.

[17]  J. Cadeddu,et al.  Long-term results of radiation therapy for prostate cancer recurrence following radical prostatectomy. , 1998, The Journal of urology.

[18]  R. Vessella,et al.  The effect of radiation therapy after radical prostatectomy in patients with elevated prostate specific antigen levels. , 1990, The Journal of urology.

[19]  E. Bergstralh,et al.  Defining prostate specific antigen progression after radical prostatectomy: what is the most appropriate cut point? , 2001, The Journal of urology.

[20]  D. Ornstein,et al.  Evaluation and management of men whose radical prostatectomies failed: results of an international survey. , 1998, Urology.

[21]  A W Partin,et al.  Natural history of progression after PSA elevation following radical prostatectomy. , 1999, JAMA.

[22]  R. Parker,et al.  Salvage radiotherapy for biochemical and clinical failures following radical prostatectomy. , 1998, The cancer journal from Scientific American.

[23]  M. Piérart,et al.  Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. , 1997, The New England journal of medicine.

[24]  S. Cha,et al.  Irradiation for locally recurrent carcinoma of the prostate following radical prostatectomy. , 1997, Urology.

[25]  P. Carroll,et al.  Is anastomotic biopsy necessary before radiotherapy after radical prostatectomy? , 2001, The Journal of urology.

[26]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[27]  L. Sullivan,et al.  Postoperative radiotherapy for stage pT3 carcinoma of the prostate: improved local control. , 1996, The Journal of urology.